May 9, 2018 / 12:12 PM / 11 days ago

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

May 9 (Reuters) - Endocyte Inc:

* Q1 LOSS PER SHARE $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 — THOMSON REUTERS I/B/E/S

* PHASE 3 VISION TRIAL ON TRACK FOR FIRST PATIENT VISIT IN Q2 2018

* CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $173.1 MILLION AT MARCH 31, 2018

* ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $130 MILLION

* ENDOCYTE - SUFFICIENT CASH TO FUND ACTIVITIES THROUGH EXPECTED END OF VISION TRIAL, POTENTIAL PROOF OF CONCEPT OF ITS EC17/CAR T-CELL THERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below